Larimar Therapeutics AI Stock Analysis
Want to see LRMR full AI Analyst Report?
Larimar Therapeutics (LRMR) AI Stock Analysis
Larimar Therapeutics
(NASDAQ:LRMR)
The score is held down primarily by weak financial performance—no revenue, widening losses, and heavy cash burn that elevates financing and dilution risk. Technicals are also soft with the stock below key longer-term moving averages and negative MACD. Offsetting these factors, corporate events are constructive, highlighted by the completed rolling FDA BLA submission for nomlabofusp and strengthened leadership, which improves the near-term catalyst profile.
Larimar Therapeutics (LRMR) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $313.73M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.33M
- Price to Earnings (P/E)
- -1.5
- Beta (1Y)
- 1.92
- Revenue Growth
- ―
- EPS Growth
- -27.00%
- Country
- US
- Employees
- 71
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Larimar Therapeutics Business Overview & Revenue Model
Company Description
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platf...
Larimar Therapeutics Financial Statement Overview
Summary
Pre-revenue profile with consistently large and widening losses (TTM net loss about -$173M) and accelerating cash burn (TTM operating cash flow about -$156M) are major weaknesses and increase financing/dilution risk. The main offset is low leverage with modest total debt (~$4–6M), which supports solvency flexibility, but does not eliminate the pressure from sustained negative cash flow.
Income Statement
12Very NegativeBalance Sheet
58NeutralCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -172.30M | -165.32M | -80.29M | -36.64M | -35.04M | -50.31M |
| Net Income | -172.60M | -165.67M | -80.60M | -36.95M | -35.35M | -50.64M |
Balance Sheet | ||||||
| Total Assets | 165.30M | 145.84M | 200.22M | 95.94M | 126.41M | 78.67M |
| Cash, Cash Equivalents and Short-Term Investments | 156.27M | 136.85M | 183.45M | 86.79M | 118.43M | 70.10M |
| Total Debt | 4.96M | 4.07M | 5.12M | 5.55M | 5.41M | 6.00M |
| Total Liabilities | 37.92M | 67.76M | 28.41M | 14.21M | 15.50M | 14.25M |
| Stockholders Equity | 127.38M | 78.08M | 171.81M | 81.72M | 110.90M | 64.41M |
Cash Flow | ||||||
| Free Cash Flow | -156.08M | -113.29M | -71.28M | -33.62M | -27.67M | -42.44M |
| Operating Cash Flow | -155.92M | -113.20M | -70.76M | -33.46M | -27.57M | -42.10M |
| Investing Cash Flow | 55.11M | 100.31M | -85.39M | 33.35M | -90.96M | 24.17M |
| Financing Cash Flow | 172.77M | 65.09M | 161.88M | 30.00K | 75.26M | 19.89M |
Larimar Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LRMR, the sentiment is Neutral. The current price of 3.02 is above the 20-day moving average (MA) of 2.50, above the 50-day MA of 2.93, and below the 200-day MA of 3.77, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 59.54 is Neutral, neither overbought nor oversold. The STOCH value of 84.30 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LRMR.
Larimar Therapeutics Risk Analysis
Larimar Therapeutics disclosed 85 risk factors in its most recent earnings report. Larimar Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
1 New RiskLarimar Therapeutics Peers Comparison
Overall Rating
LRMR50Neutral
OMER48Neutral
CADL43Neutral
NMRA43Neutral
FHTX41Neutral
VNDA39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $313.73M | -1.52 | -137.39% | ― | ― | -27.00% | |
| 48Neutral | $1.27B | 9.16 | -109.40% | ― | ― | ― | |
| 43Neutral | $486.36M | -4.19 | -88.58% | ― | ― | -171.31% | |
| 43Neutral | $80.59M | -0.35 | -242.28% | ― | ― | 21.31% | |
| 41Neutral | $124.12M | 29.57 | -14.17% | ― | 357.33% | ― | |
| 39Underperform | $241.27M | -0.86 | -106.94% | ― | 8.11% | -222.50% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| LRMR | Larimar Therapeutics, Inc. | 3.02 | -0.51 | -14.45% | |
| OMER | Omeros Corporation | 17.49 | 8.41 | 92.62% | |
| VNDA | Vanda Pharmaceuticals | 3.99 | -0.41 | -9.32% | |
| FHTX | Foghorn Therapeutics, Inc. | 2.07 | -2.74 | -56.96% | |
| CADL | Candel Therapeutics, Inc. | 6.20 | 1.47 | 31.08% | |
| NMRA | Neumora Therapeutics, Inc. | 0.43 | -2.16 | -83.47% |
Larimar Therapeutics Corporate Events
Larimar Therapeutics Completes Rolling FDA BLA Submission for Nomlabofusp
PositiveOn November 9, 2026, Larimar announced completion of its rolling BLA submission to the FDA seeking accelerated approval of nomlabofusp for patients with Friedreich’s ataxia. The investigational protein replacement therapy is designed to deliver human...
Larimar Therapeutics Appoints New President and COO
PositiveOn September 29, 2026, Larimar Therapeutics appointed John B. Harlow Jr. as president and chief operating officer under an employment agreement that includes a $560,000 base salary, performance-based bonus eligibility, and standard executive severanc...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
